Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.

This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; M. Liu, PhD, M. Glynn, MS, K. Emeanuru, MPH, Corrona, LLC, Waltham; L.R. Harrold, MD, MPH, Corrona, LLC, Waltham, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P.J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA. All authors contributed to the interpretation of the results. AO has received grant/research support from Pfizer Inc. and Novartis and has served as a consultant to AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc., and Takeda. ML, MG, and KE have worked on Corrona-contracted subscriptions for AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Merck, UCB, and Valeant. LRH is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc., and has served as a consultant to AbbVie, Bristol Myers Squibb and Roche. SR and BG are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. PJM has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc., Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc., and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sanofi, Sun, and UCB. Address correspondence to Dr. A. Ogdie, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 23, 2020.